Difference between revisions of "SDTM in RDF"

From PHUSE Wiki
Jump to: navigation, search
m
m
Line 70: Line 70:
  
 
----
 
----
[[Category:Name]]
+
[[Category:SemanticTechnology]]

Revision as of 14:20, 30 May 2013

SDTM Standards in RDF

Standards Documents

Document Description Document Version URL Represent in RDF?
SDTM v1.2, IG v3.1.2 Zip Archive Done
SDTM v1.2, IG v3.1.2, Amendment 1 PDF TBD
SDTM v1.3, IG v3.1.3 Zip Archive,
Metadata tables in Members Only
Y
Medical Device Supplement v1.0 PDF TBD
Polycystic Kidney Disease User Guide v1.0 (Provisional) Zip Archive TBD
Parkinson's Disease User Guide v1.0 (Provisional) Zip Archive TBD
Virology User Guide v1.0 (Provisional) PDF TBD
Pain User Guide v1.0 (Provisional) Zip Archive TBD
Tuberculosis User Guide v1.0 (Provisional) Zip Archive TBD
Alzheimer's Disease/Mild Cognitive Impairment User Guide v1.0 PDF TBD

Notes on Documents

  • We agreed that as a first stab we'd stick to the non-provisional standards.
  • SDTM 3.1.2 Amendment 1 is more of the same and should be able to be easily added to the model. AE gets 10 new allowable variables, DM gets 8 new allowable variables. Content is in PDF, but in tabular format in the PDF and DanBoisvert could turn it into .xls if we need to.
  • Alzheimer's Disease/Mild Cognitive Impairment - This document is more of an explanation of how to apply the SDTM 3.1.2 to Alzheimer trials. No new variables are identified. There is something about a 'Non Subject' domain that is under consideration by the SDS team (sounds interesting...collecting data about family history but the data isn't about the patient themselves).
Page 9 - See Non-Subject Data Supplement v1.0 to SDTMIG for NS domain tables -This domain is under review with the CDISC SDS team, following the CDISC domain development process. This section will be updated upon release of the approved domain.The SDTMIG:NS is intended to guide the organization, structure, and format of standard data for persons who are not the subject in a clinical trial, but about whom data has been collected, when that data will be submitted to a regulatory authority such as the US Food and Drug Administration (FDA). This guide describes the implementation of any data tabulations collected about persons of interest in a clinical trial who are not the subject in the trial. These non-subject persons may or may not have a relationship to a clinical trial subject.

Other Documents